LTR Pharma Ltd Advances Erectile Dysfunction Treatment with Nasal Spray

LTR Pharma Limited (ASX: LTP) has reached a significant milestone with the successful completion of the first dosing for patients in the company’s pivotal bioequivalence clinical study of a nasal spray designed for men with erectile dysfunction (ED).

Looking to revolutionize the PDE5 inhibitor market, LTR has obtained exclusive worldwide rights to develop, manufacture, and market SPONTAN through a licensing agreement with SDS.

Disrupt blockbuster market

This move comes as the market for such treatments is projected to reach U.S.$6.0 billion by 2028.

LTR is looking to disrupt the blockbuster PDE5 inhibitor market with the first nasal spray in the treatment of ED.

Nasal sprays offer advantages in absorption rates over oral formulations, facilitating faster delivery to the bloodstream.

LTR is focused on changing the method of administration of Vardenafil, an existing and approved drug already in global markets since 2003.

Repurposed drugs with innovative delivery methods can gain expedited market access in both the US and Australia.

ED is a condition affecting a person’s ability to achieve or maintain an erection suitable for sexual intercourse.

It can have significant short-term and long-term implications, including relationship strain and mental health issues.

Focused on enhancing men’s health, LTR Pharma aims to commercialize SPONTAN, an innovative nasal spray treatment for ED.

The ongoing clinical study evaluates the relative bioavailability of SPONTAN compared to oral Vardenafil, commonly known as Levitra, a widely used PDE5 oral tablet.

Pathway

SPONTAN nasal spray represents a potential breakthrough in ED treatment, offering a discreet and efficient alternative to conventional methods.

The study, designed to meet FDA and other market requirements, involves 18 patients in a single-dose, randomized, open-label, crossover comparison of SPONTAN nasal spray and Vardenafil tablets under fasting conditions.

With results anticipated by mid-2024, LTR Pharma is optimistic about the potential impact of SPONTAN nasal spray on the ED treatment landscape.

Well funded

LTR Pharma has demonstrated promising results in its Phase I Human Proof of Concept, indicating a sixfold faster onset of action compared to oral PDE5 inhibitors like Viagra.

The company is well-funded, having raised $7 million as part of its ASX IPO in December 2023.

Additionally, LTR Pharma has secured a commercial manufacturing partnership with ASX-listed Mayne Pharma (ASX: MYX), enhancing its capabilities for progressing its treatment to market.

Articles of Interest